Sana Biotechnology (NASDAQ: SANA) net income
Sana Biotechnology reported a net loss of $244.2m for fiscal 2025; in fiscal 2024 it reported a net loss of $266.8m. Earnings per share were −$0.96.
Fiscal 2025 is the highest of the 6 fiscal years on record for Sana Biotechnology. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$244.2m | — | — | −$0.96 |
| 2024 | −$266.8m | — | — | −$1.16 |
| 2023 | −$283.3m | — | — | −$1.46 |
| 2022 | −$269.5m | — | — | −$1.43 |
| 2021 | −$355.9m | — | — | −$2.14 |
| 2020 | −$285.3m | — | — | −$21.92 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Sana Biotechnology net income compared with its sector
By net income for its latest fiscal year, Sana Biotechnology ranks 433rd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 431st | Alumis | −$243.3m | −1,011.7% |
| 432nd | Prothena Corporation Public | −$244.1m | −2,520.6% |
| 433rd | Sana Biotechnology | −$244.2m | — |
| 434th | Tempus AI | −$245.0m | −19.3% |
| 435th | Precigen | −$250.6m | −2,588.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Sana Biotechnology
- How much did Sana Biotechnology earn in fiscal 2025?
- Sana Biotechnology reported a net loss of $244.2m for fiscal 2025. In fiscal 2024 it reported a net loss of $266.8m.
- What are the earnings per share of Sana Biotechnology?
- They were −$0.96 in fiscal 2025, compared with −$1.16 in fiscal 2024.
- Where does Sana Biotechnology rank in its sector by net income?
- It ranks 433rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Sana Biotechnology come from?
- From the annual report (Form 10-K) that Sana Biotechnology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Sana Biotechnology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Sana Biotechnology: the Sana Biotechnology page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.